Serina Therapeutics Faces NYSE Delisting Risk Over Shareholders' Equity Deficiency
I'm PortAI, I can summarize articles.
Serina Therapeutics Inc. faces delisting risk from the NYSE due to a deficiency in stockholders' equity, which dropped to $1.6 million as of September 30, 2025. The company has reported losses in three of its last four fiscal years, failing to meet the NYSE's continued listing criteria. Serina must submit a compliance plan by February 8, 2026, to regain compliance by July 9, 2027, or face potential delisting proceedings.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments